Misplaced Pages

IM-250

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Antiherpes drug candidate
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)
IM-250
Names
IUPAC name (S)-2--N-methyl-N-acetamide
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
PubChem CID
InChI
  • InChI=1S/C20H19F2N3O2S2/c1-12-19(29(3,23)27)28-20(24-12)25(2)18(26)10-13-4-6-14(7-5-13)16-11-15(21)8-9-17(16)22/h4-9,11,23H,10H2,1-3H3Key: JDZTWDISDHLKCR-UHFFFAOYSA-N
SMILES
  • CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=C(C=CC(=C3)F)F)S(=N)(=O)C
Properties
Chemical formula C20H19F2N3O2S2
Molar mass 435.51 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references
Chemical compound

IM-250 is an anti-herpetic drug candidate developed by Innovative Molecules Gmbh. The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.

Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.

See also

References

  1. Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris; Hamprecht, Klaus; Grunwald, Thomas; Bernstein, David I.; Kleymann, Gerald (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine. 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.
  2. "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021.
  3. "Small molecule fights active and latent herpes infections in rodents".
  4. Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal. 28 (56): e202201993. doi:10.1002/chem.202201993. PMID 35789054.


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:
IM-250 Add topic